INCY News and Press, Incyte Corporation From 09/30/21

OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata - Potential first-in-disease treatment for millions of adults worldwide living with alopecia areata (AA) - - Saf...

Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases - Syndax to receive $ 152 million in cash ($117 million upfront plus a $35 million equity investment, with po...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q2-2021 13F filings, the consensus holdings were updated. 6 stocks were removed and 6 added from the univ...

The following slide deck was published by Incyte Corporation in conjunction with this event. For further details see: Incyte Corporation (INCY) Opzelura (ruxolitinib) cream FDA Approval Presentation - Slideshow

MONTREAL, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement with Incyte Biosciences International Sàrl, the Swiss-bas...

- Jakafi is approved for treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older - Today’s approval marks the fourth FDA-approved indication for Jakafi, which received FDA-approval in 2019 for st...

The stock market got off to a strong start on Wednesday, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) benefited from more positive sentiment on Wall Street. As of 10 a.m. EDT, the Nasdaq was up more than half a percent, continuing to claw back some of the ground it lost in Monday's...

- Opzelura is the first and only topical Janus kinase (JAK) inhibitor approved in the United States - In Phase 3 studies, Opzelura significantly reduced the skin inflammation and itch associated with AD - Investor conference call and webcast scheduled for September 22,...

You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...